^
Association details:
| Biomarker: | HRD |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) + Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/20/2023
Excerpt:
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for:...In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Secondary therapy:
enzalutamide tablet
Source:
Published date:
08/07/2023
Excerpt:
Prostate Cancer: SYSTEMIC THERAPY FOR M1 CRPC…Useful in certain circumstances…Talazoparib/enzalutamide for HRRm…
Source:
Title:
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Published date:
12/05/2023
Excerpt:
Combining talazoparib with enzalutamide significantly improved radiographic progression-free survival in patients with mCRPC harboring HRR gene alterations, supporting talazoparib plus enzalutamide as a potential first-line treatment for these patients.
DOI:
10.1038/s41591-023-02704-x
Trial ID:
Source:
Title:
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Published date:
05/25/2023
Excerpt:
TALA + ENZA delayed time to PSA progression, cytotoxic chemotherapy, and antineoplastic therapy, and improved ORR, PSA response, and investigator-assessed PFS2….TALA + ENZA demonstrated a statistically significant and clinically meaningful improvement in rPFS over standard of care ENZA as 1L treatment for pts with mCRPC and HRR gene alterations...
Secondary therapy:
enzalutamide tablet
DOI:
10.1200/JCO.2023.41.16_suppl.5004
Trial ID:
